Eiger BioPharmaceuticals Inc Stock, NASDAQ:EIGR
2155 Park Boulevard, 2155 Park Boulevard, Palo Alto, California 94306-1543
United States of America
Number of Employees: 43
Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.